IL4R and asthma: This hypothesis is indirectly supported by the efficacy of dupilumab, which inhibits both IL-4 and IL-13 signaling mediated by IL-4Rα, in patients with severe uncontrolled asthma (Castro et al., 2018; Rabe et al., 2018).